An MLH1 haplotype is over-represented on chromosomes carrying an HNPCC predisposing mutation in MLH1

被引:9
|
作者
Hutter, P [1 ]
Wijnen, J
Rey-Berthod, C
Thiffault, I
Verkuijlen, P
Farber, D
Hamel, N
Bapat, B
Thibodeau, SN
Burn, J
Wu, J
MacNamara, E
Heinimann, K
Chong, G
Foulkes, WD
机构
[1] Hop Valaisans, Inst Cent, Genet Unit, Sion, Switzerland
[2] Leiden Univ, Med Ctr, Dept Human & Clin Genet, Leiden, Netherlands
[3] McGill Univ, Sir MB Davis Jewish Gen Hosp, Dept Diagnost Med, Montreal, PQ, Canada
[4] McGill Univ, Sir MB Davis Jewish Gen Hosp, Dept Med, Montreal, PQ, Canada
[5] McGill Univ, Sir MB Davis Jewish Gen Hosp, Dept Oncol, Montreal, PQ, Canada
[6] McGill Univ, Res Inst, Ctr Hlth, Montreal, PQ, Canada
[7] Mt Sinai Hosp, Dept Pathol & Lab Med, Toronto, ON M5G 1X5, Canada
[8] Mayo Clin, Mol Genet Lab, Rochester, MN USA
[9] Univ Newcastle Upon Tyne, Inst Human Genet, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England
[10] St Marys Hosp, NW Reg Genet Lab, Manchester M13 0JH, Lancs, England
[11] Univ Clin, Div Med Genet, Res Grp Human Genet, Basel, Switzerland
[12] McGill Univ, Dept Oncol & Human Genet, Program Canc Genet, Montreal, PQ, Canada
关键词
D O I
10.1136/jmg.39.5.323
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Background: The mismatch repair gene, MLH1, appears to occur as two main haplotypes at least in white populations. These are referred to as A and G types with reference to the A/G polymorphism at IVS14-19. On the basis of preliminary experimental data, we hypothesised that deviations from the expected frequency of these two haplotypes could exist in carriers of disease associated MLH1 germline mutations. Methods: We assembled a series (n = 119) of germline MLH1 mutation carriers in whom phase between the haplotype and the mutation had been conclusively established. Controls, without cancer, were obtained from each contributing centre. Cases and controls were genotyped for the polymorphism in IVS14. Results: Overall, 66 of 119 MLH1 mutations occurred on a G haplotype (55.5%), compared with 315 G haplotypes on 804 control chromosomes (39.2%, p=0.001). The odds ratio (OR) of a mutation occurring on a G rather than an A haplotype was 1.93 (95% Cl 1.29 to 2.91). When we compared the haplotype frequencies in mutation bearing chromosomes carried by people of different nationalities with those seen in pooled controls, all groups showed a ratio of A/G haplotypes that was skewed towards G, except the Dutch group. On further analysis of the type of each mutation, it was notable that, compared with control frequencies, deletion and substitution mutations were preferentially represented on the G haplotype (p=0.003 and 0.005, respectively). Conclusion: We have found that disease associated mutations in MLH1 appear to occur more often on one of only two known ancient haplotypes. The underlying reason for this observation is obscure, but it is tempting to suggest a possible role of either distant regulatory sequences or of chromatin structure influencing access to DNA sequence. Alternatively, differential behaviour of otherwise similar haplotypes should be considered as prime areas for further study.
引用
收藏
页码:323 / 327
页数:5
相关论文
共 50 条
  • [21] Regulation of the MLH1–MLH3 endonuclease in meiosis
    Elda Cannavo
    Aurore Sanchez
    Roopesh Anand
    Lepakshi Ranjha
    Jannik Hugener
    Céline Adam
    Ananya Acharya
    Nicolas Weyland
    Xavier Aran-Guiu
    Jean-Baptiste Charbonnier
    Eva R. Hoffmann
    Valérie Borde
    Joao Matos
    Petr Cejka
    Nature, 2020, 586 : 618 - 622
  • [22] MLH1 Differential Allelic Expression in Mutation Carriers and Controls
    Santibanez Koref, Mauro
    Wilson, Valerie
    Cartwright, Nicola
    Cunnington, Michael S.
    Mathers, John C.
    Bishop, D. Timothy
    Curtis, Ann
    Dunlop, Malcolm G.
    Burn, John
    ANNALS OF HUMAN GENETICS, 2010, 74 : 479 - 488
  • [23] Genetic and epigenetic modification of MLH1
    Perucho, M
    AMERICAN JOURNAL OF PATHOLOGY, 2000, 157 (03): : 1052 - 1052
  • [24] MLH1 immunoreactivity in prostatic adenocarcinoma
    Yang, XJ
    Lin, F
    Ruddy, T
    Han, M
    Catalona, WJ
    MODERN PATHOLOGY, 2006, 19 : 168A - 168A
  • [25] MLH1 immunoreactivity in prostatic adenocarcinoma
    Yang, XJ
    Lin, F
    Ruddy, T
    Han, M
    Catalona, WJ
    LABORATORY INVESTIGATION, 2006, 86 : 168A - 168A
  • [26] Cumulative incidence of extracolonic and colorectal cancers in MLH1 and MSH2 mutation carriers of HNPCC
    Lin, KM
    Shashidharan, M
    Ternent, CA
    Thorson, AG
    Blatchford, GJ
    Christensen, MA
    Lemon, S
    Lynch, HT
    GASTROENTEROLOGY, 1997, 112 (04) : A1454 - A1454
  • [27] Punctate Pattern Nuclear MLH1 Immunoexpression Without Classic Nuclear MLH1 Staining is an Artifact in MMR Deficient Endometrial Cancer that Merits MLH1 Promoter Methylation Testing
    Bhardwaj, Swati
    Rabban, Joseph
    LABORATORY INVESTIGATION, 2023, 103 (03) : S861 - S861
  • [28] Methylation of the MLH1 promoter results in loss of MLH1 expression and drug resistance in ovarian tumour cells
    Strathdee, G
    MacKean, M
    Brown, R
    BRITISH JOURNAL OF CANCER, 1998, 78 : 20 - 20
  • [29] Heritable constitutional MLH1 epimutation is associated with a novel MLH1 sequence variant in a family with Lynch syndrome
    Payne, Stewart
    Patel, D.
    Bourdon, L. V.
    Dover, K. M.
    Harrison, R.
    Shannon, N.
    Pasalodos, S.
    Jassi, R.
    JOURNAL OF MEDICAL GENETICS, 2012, 49 : S51 - S51
  • [30] MLH1 constitutional and somatic methylation in patients with MLH1 negative tumors fulfilling the revised Bethesda criteria
    Crucianelli, Francesca
    Tricarico, Rossella
    Turchetti, Daniela
    Gorelli, Greta
    Gensini, Francesca
    Sestini, Roberta
    Giunti, Laura
    Pedroni, Monica
    de Leon, Maurizio Ponz
    Civitelli, Serenella
    Genuardi, Maurizio
    EPIGENETICS, 2014, 9 (10) : 1431 - 1438